Joel Greenblatt’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $251K | Sell |
803
-2,807
| -78% | -$830K | ﹤0.01% | 1749 |
|
|
2026
Q2 | $1.14M | Sell |
3,610
-562
| -13% | -$132K | ﹤0.01% | 1322 |
|
|
2026
Q1 | $833K | Sell |
4,172
-5,174
| -55% | -$1.02M | ﹤0.01% | 1363 |
|
|
2025
Q4 | $1.77M | Sell |
9,346
-129
| -1% | -$24.8K | 0.01% | 1074 |
|
|
2025
Q3 | $1.68M | Buy |
+9,475
| New | +$1.41M | 0.01% | 1049 |
|
|
2025
Q2 | – | Sell |
-6,912
| Closed | -$727K | – | 1710 |
|
|
2025
Q1 | $727K | Buy |
+6,912
| New | +$782K | 0.01% | 1101 |
|
|
2024
Q1 | – | Sell |
-4,183
| Closed | -$299K | – | 1424 |
|
|
2023
Q4 | $299K | Sell |
4,183
-3,300
| -44% | -$195K | 0.01% | 1139 |
|
|
2023
Q3 | $448K | Sell |
7,483
-1,799
| -19% | -$118K | 0.01% | 993 |
|
|
2023
Q2 | $669K | Buy |
9,282
+5,037
| +119% | +$378K | 0.01% | 887 |
|
|
2023
Q1 | $312K | Buy |
+4,245
| New | +$302K | 0.01% | 1115 |
|
|
2022
Q4 | – | Sell |
-4,543
| Closed | -$391K | – | 1268 |
|
|
2022
Q3 | $391K | Buy |
4,543
+1,400
| +45% | +$132K | 0.01% | 905 |
|
|
2022
Q2 | $280K | Sell |
3,143
-1,437
| -31% | -$131K | 0.01% | 962 |
|
|
2022
Q1 | $515K | Buy |
4,580
+1,122
| +32% | +$130K | 0.02% | 794 |
|
|
2021
Q4 | $534K | Buy |
3,458
+1,051
| +44% | +$156K | 0.02% | 753 |
|
|
2021
Q3 | $335K | Sell |
2,407
-155
| -6% | -$19.2K | 0.01% | 780 |
|
|
2021
Q2 | $336K | Buy |
2,562
+526
| +26% | +$70.1K | 0.01% | 803 |
|
|
2021
Q1 | $310K | Sell |
2,036
-1,679
| -45% | -$254K | 0.01% | 831 |
|
|
2020
Q4 | $369K | Buy |
+3,715
| New | +$340K | 0.01% | 784 |
|
|
2020
Q1 | – | Sell |
-2,468
| Closed | -$257K | – | 1148 |
|
|
2019
Q4 | $257K | Buy |
2,468
+343
| +16% | +$36.7K | ﹤0.01% | 982 |
|
|
2019
Q3 | $212K | Sell |
2,125
-62,546
| -97% | -$6.29M | ﹤0.01% | 998 |
|
|
2019
Q2 | $7.38M | Buy |
64,671
+39,236
| +154% | +$4.63M | 0.12% | 243 |
|
|
2019
Q1 | $3.2M | Buy |
25,435
+8,878
| +54% | +$1.08M | 0.05% | 416 |
|
|
2018
Q4 | $2.25M | Sell |
16,557
-11,254
| -40% | -$1.92M | 0.03% | 467 |
|
|
2018
Q3 | $7.63M | Buy |
27,811
+13,820
| +99% | +$3.34M | 0.11% | 267 |
|
|
2018
Q2 | $2.9M | Sell |
13,991
-2,319
| -14% | -$415K | 0.04% | 425 |
|
|
2018
Q1 | $2.69M | Sell |
16,310
-35,790
| -69% | -$5.67M | 0.04% | 452 |
|
|
2017
Q4 | $7.13M | Buy |
+52,100
| New | +$7.24M | 0.1% | 293 |
|
|
2017
Q2 | – | Sell |
-117,749
| Closed | -$12.5M | – | 1032 |
|
|
2017
Q1 | $12.5M | Buy |
117,749
+83,784
| +247% | +$8.84M | 0.16% | 217 |
|
|
2016
Q4 | $3.45M | Sell |
33,965
-4,266
| -11% | -$432K | 0.04% | 437 |
|
|
2016
Q3 | $3.9M | Sell |
38,231
-33,639
| -47% | -$3.96M | 0.05% | 397 |
|
|
2016
Q2 | $8.57M | Buy |
71,870
+50,048
| +229% | +$5.95M | 0.1% | 307 |
|
|
2016
Q1 | $2.34M | Buy |
+21,822
| New | +$2.13M | 0.03% | 559 |
|
|
2015
Q1 | – | Sell |
-3,766
| Closed | -$200K | – | 970 |
|
|
2014
Q4 | $200K | Sell |
3,766
-548,287
| -99% | -$28.6M | ﹤0.01% | 914 |
|
|
2014
Q3 | $25.9M | Buy |
552,053
+496,561
| +895% | +$26.4M | 0.26% | 143 |
|
|
2014
Q2 | $3.46M | Buy |
+55,492
| New | +$3.61M | 0.04% | 450 |
|
|
2014
Q1 | – | Sell |
-13,803
| Closed | -$726K | – | 1047 |
|
|
2013
Q4 | $726K | Buy |
13,803
+7,667
| +125% | +$400K | 0.02% | 688 |
|
|
2013
Q3 | $266K | Buy |
+6,136
| New | +$277K | 0.01% | 811 |
|
Other funds holding LGND
Joel Greenblatt's LGND Position: Q3 2026 in Review
Joel Greenblatt reduced its Ligand Pharmaceuticals (LGND) stake by 78% in Q3 2026, selling an estimated $830K and leaving 803 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #1749.
Joel Greenblatt first reported a position in LGND in Q3 2013 and has held it in 37 quarters since. The position peaked at $25.9M in Q3 2014. 433 funds tracked by Wall St. Rank hold LGND as of Q3 2026.
- Joel Greenblatt held 803 shares of Ligand Pharmaceuticals worth $251K as of Q3 2026.
- Joel Greenblatt sold 2,807 Ligand Pharmaceuticals shares in Q3 2026, an estimated $830K.
- Ligand Pharmaceuticals made up ﹤0.01% of Joel Greenblatt's portfolio in Q3 2026, its #1749 holding.
- Joel Greenblatt first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 37 quarters since.
- Joel Greenblatt's Ligand Pharmaceuticals position peaked at $25.9M in Q3 2014.
- 433 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.
Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.